Clinical Trial: Phase II Study of LM-24C5

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07387081) titled 'Phase II Study of LM-24C5' on Dec. 02, 2025.

Brief Summary: This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor

Study Start Date: Dec. 15, 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor Cancer

Intervention: DRUG: LM-24C5

Q2W Administered intravenously Drug: Penpulimab Q2W Administered intravenously Drug: Docetaxel Q3W Administered intravenously

DRUG: LM-24C5

Q2W Administered intravenously Drug: Penpulimab Q2W Administered intravenously Drug:Trifluridine and Tipiracil Hydrochloride Tablets BID,Oral Administ...